{"filing":{"accession_number":"0001193125-26-399383","cik":"0001937653","ticker":"ZYME","company_name":"Zymeworks Inc.","form":"8-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"d270232d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1937653/000119312526399383/d270232d8k.htm"},"events":[{"id":34579,"run_id":31824,"accession_number":"0001193125-26-399383","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.97,"summary":"Zymeworks completed its acquisition of Theravance Biopharma on September 22, 2026, advancing its strategy to build a diversified revenue-generating biotechnology company. The transaction includes a Contingent Value Rights Agreement governing CVRs tied to ampreloxetine monetization and commercial milestones, and a $350 million senior secured Note Purchase Agreement with OCM IP Healthcare Portfolio LP.","company_name":"Zymeworks Inc.","ticker":"ZYME","filing_date":"2026-09-23","form":"8-K","submitted_at":null,"items":[{"id":38337,"accession_number":"0001193125-26-399383","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 1.01 discloses entry into material definitive agreements in connection with the consummation of the Merger between Zymeworks and Theravance Biopharma, completed on September 22, 2026. The filing describes two key agreements: (1) a Contingent Value Rights Agreement governing CVRs tied to ampreloxetine monetization and commercial milestones, and (2) a $350 million senior secured Note Purchase Agreement with OCM IP Healthcare Portfolio LP. The press release confirms \"Zymeworks Completes Acquisition of Theravance Biopharma,\" establishing this as a material acquisition transaction that would significantly affect investor assessment of the registrant's financial position, asset base, and future cash flows.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:10:59.188364+00:00","company_name":"","ticker":null,"filing_date":""},{"id":38338,"accession_number":"0001193125-26-399383","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses completion of Zymeworks' acquisition of Theravance Biopharma, a material M\u0026A transaction. The press release states \"Zymeworks Inc. (Nasdaq: ZYME)...today completed the previously announced acquisition of Theravance Biopharma\" and describes it as \"further advancing Zymeworks' strategy to build a diversified revenue-generating biotechnology company.\" This is a completed acquisition of a significant asset, directly falling under Item 2.01 (Completion of Acquisition or Disposition of Assets) and constituting a material event affecting the registrant's business and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:10:59.188364+00:00","company_name":"","ticker":null,"filing_date":""},{"id":38339,"accession_number":"0001193125-26-399383","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 2.03 incorporates by reference Item 1.01, which covers the Note Purchase Agreement and Guaranty and Security Agreement related to the acquisition. The supplemental exhibit (EX-99.1) confirms that Zymeworks \"completed the previously announced acquisition of Theravance Biopharma,\" which is a material acquisition that advances Zymeworks' strategy to build a diversified revenue-generating biotechnology company. The completion of this M\u0026A transaction is the principal event disclosed.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:10:59.188364+00:00","company_name":"","ticker":null,"filing_date":""},{"id":38340,"accession_number":"0001193125-26-399383","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing announces the completion of Zymeworks' acquisition of Theravance Biopharma on September 23, 2026. The press release explicitly states \"Zymeworks Inc. (Nasdaq: ZYME)...today completed the previously announced acquisition of Theravance Biopharma\" and describes this as \"further advancing Zymeworks' strategy to build a diversified revenue-generating biotechnology company.\" This is a material M\u0026A completion event that would significantly affect investor assessment of the registrant's strategic position and asset base.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:10:59.188364+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38337,"accession_number":"0001193125-26-399383","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 1.01 discloses entry into material definitive agreements in connection with the consummation of the Merger between Zymeworks and Theravance Biopharma, completed on September 22, 2026. The filing describes two key agreements: (1) a Contingent Value Rights Agreement governing CVRs tied to ampreloxetine monetization and commercial milestones, and (2) a $350 million senior secured Note Purchase Agreement with OCM IP Healthcare Portfolio LP. The press release confirms \"Zymeworks Completes Acquisition of Theravance Biopharma,\" establishing this as a material acquisition transaction that would significantly affect investor assessment of the registrant's financial position, asset base, and future cash flows.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:10:59.188364+00:00","company_name":"Zymeworks Inc.","ticker":"ZYME","filing_date":"2026-09-23"},{"id":38338,"accession_number":"0001193125-26-399383","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses completion of Zymeworks' acquisition of Theravance Biopharma, a material M\u0026A transaction. The press release states \"Zymeworks Inc. (Nasdaq: ZYME)...today completed the previously announced acquisition of Theravance Biopharma\" and describes it as \"further advancing Zymeworks' strategy to build a diversified revenue-generating biotechnology company.\" This is a completed acquisition of a significant asset, directly falling under Item 2.01 (Completion of Acquisition or Disposition of Assets) and constituting a material event affecting the registrant's business and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:10:59.188364+00:00","company_name":"Zymeworks Inc.","ticker":"ZYME","filing_date":"2026-09-23"},{"id":38339,"accession_number":"0001193125-26-399383","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 2.03 incorporates by reference Item 1.01, which covers the Note Purchase Agreement and Guaranty and Security Agreement related to the acquisition. The supplemental exhibit (EX-99.1) confirms that Zymeworks \"completed the previously announced acquisition of Theravance Biopharma,\" which is a material acquisition that advances Zymeworks' strategy to build a diversified revenue-generating biotechnology company. The completion of this M\u0026A transaction is the principal event disclosed.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:10:59.188364+00:00","company_name":"Zymeworks Inc.","ticker":"ZYME","filing_date":"2026-09-23"},{"id":38340,"accession_number":"0001193125-26-399383","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing announces the completion of Zymeworks' acquisition of Theravance Biopharma on September 23, 2026. The press release explicitly states \"Zymeworks Inc. (Nasdaq: ZYME)...today completed the previously announced acquisition of Theravance Biopharma\" and describes this as \"further advancing Zymeworks' strategy to build a diversified revenue-generating biotechnology company.\" This is a material M\u0026A completion event that would significantly affect investor assessment of the registrant's strategic position and asset base.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:10:59.188364+00:00","company_name":"Zymeworks Inc.","ticker":"ZYME","filing_date":"2026-09-23"}]}